Pulmonx Reports Q2 Revenue Growth Amid Ongoing Losses and Rising Costs

Pulmonx Corporation (NASDAQ: LUNG) has released its financial results for the second quarter of 2025, demonstrating growth in revenue but continuing to incur significant losses. The company specializes in minimally invasive treatments for severe emphysema using its flagship product, the Zephyr Valve.

Key Highlights from the Financial Results:

• Revenue Growth: Reported revenue for Q2 2025 was $23.9 million, a 14.8% increase compared to $20.8 million in Q2 2024.
• Cost of Goods Sold (COGS): COGS increased to $6.7 million, up 21.5% from $5.5 million in the previous year, which slightly affected gross margin, decreasing to 72.1% versus 73.7%.
• Net Loss: The company reported a net loss of $15.2 million for Q2 2025, a modest improvement from a loss of $15.3 million in Q2 2024.
• Accumulated Deficit: As of June 30, 2025, Pulmonx's accumulated deficit stood at $497.2 million.
• Cash Position: The company held cash, cash equivalents, and marketable securities totaling $84.2 million.
• Operating Expenses: Total operating expenses were $32.0 million, a slight increase over $30.9 million from the previous year, mainly driven by $26.7 million in selling, general and administrative costs.
• Research and Development: R&D expenses remained relatively stable at $5.3 million in Q2 2025 compared to $5.6 million in Q2 2024.

Positive Aspects:

• Growth in both domestic and international revenue, indicating successful market expansion strategies.
• Stable R&D investment reflecting ongoing commitment to product development and clinical studies.
• A healthy cash balance which provides operational runway for future growth initiatives.

Negative Aspects:

• Continuing large net losses signal challenges in reaching profitability despite revenue growth.
• Increase in cost of goods sold suggests rising manufacturing costs that may affect margins.
• Dependence on a single product (the Zephyr Valve), which increases vulnerability to market changes or competition.

Overall, while Pulmonx Corporation is on a growth trajectory with improvements in revenue, the persistent losses and rising costs highlight significant challenges ahead. The company's ability to navigate these financial pressures and expand its product offerings will be crucial for its long-term sustainability in the competitive medical technology space.